ViroGates announces initial data on the use of suPARnostic® in the triaging of patients with COVID-19 symptoms
The groups looked specifically at patients with a positive diagnostic test for the coronavirus and how the clinical symptoms developed over 14 days. About 20-30% of patients with SARS-CoV-2 infection progress to develop severe respiratory failure (SRF). The researchers looked at whether suPAR levels at admission can predict which patients will develop SRF during a follow-up of 14 days from the first presentation. The data showed that patients with a suPAR level above 6ng/ml had a significant (p < 0.0001) 16 times higher risk of developing SRF than those with a suPAR level below 6 ng/ml. The researches also looked at other biomarkers such as CRP and Neutrophils and none of these could predict the development of SRF.
The findings in the letter suggest that suPAR may early trace COVID-19 patients who develop SRF. Early identification of high-risk COVID-19 patients may be useful when deciding to admit or discharge patients to:
- Decrease unnecessary hospitalizations of low-risk patients that take up limited hospital beds in an already overburdened healthcare system
- Lower the risk of sending home patients that require hospitalization and intensified management
Jakob Knudsen, Chief Executive Officer of ViroGates, says: ”We are very enthusiastic about these new data. We look forward to seeing data in larger populations and with longer follow up, but these early findings show that suPARnostic® is indeed capable of supporting front line health care personnel in early triaging and identifying patients that need special attention and patients that can be observed in home quarantine or less urgent and resource-demanding environments than an Intensive Care Unit or isolation wards at the hospital.”
The study is published as a Research Letter in the Critical Care Journal and can be found as open access at https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-02897-4
For further information please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Information om ViroGates
About ViroGates
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.
ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
About suPAR and suPARnostic®
suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Siemens ADVIA XPT instruments and Roche Diagnostics’ cobas instruments. ViroGates works with partners to develop solutions for other platforms.
Følg pressemeddelelser fra ViroGates
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra ViroGates
Webinar i forbindelse med den igangværende fortegningsemission i ViroGates med Stokk.io7.12.2023 15:13:36 CET | Pressemeddelelse
BIRKERØD, DANMARK – ViroGates’ fortegningsemission finder sted i perioden 30. november til 13. december 2023, hvor eksisterende aktionærer i kraft af tildelte tegningsretter kan købe nye aktier i forholdet 1:1. Nye investorer, som er interesserede i at købe aktier, har mulighed for at købe tegningsretter (Ticker ”VIRO T”) via deres bank. Udbuddet er på maksimalt DKK 15.077.282 før emissionsomkostninger ("Udbuddet"). I Udbuddet er der afgivet bindende tegningsforpligtelser op til DKK 7.309.274, svarende til ca. 48 procent af Udbuddet, fra tre eksisterende aktionærer og repræsentanter fra bestyrelse og direktion. Udbuddet blev godkendt på en ekstraordinær generalforsamling den 24. november 2023. ViroGates inviterer i forbindelse med emissionen til en online præsentation og Q&A for alle investorer. Det er allerede nu muligt at tilmelde sig webinaret, og der kan via tilmeldingslinket også stilles spørgsmål på forhånd. Det vil ligeså være muligt at stille spørgsmål på Q&A-siden mens webinar
SAVE-MORE study on the effect of suPARnostic® guided anakinra treatment in patients with COVID-19 pneumonia published in Nature Medicine6.9.2021 15:25:56 CEST | Press release
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today reports that Nature Medicine has published the previously announced positive results from the investigator-driven phase III SAVE-MORE study evaluating the effect of suPARnostic® guided anakinra plus standard of care treatment (SOC) in patients with moderate-to-severe COVID-19 pneumonia. The study demonstrated that patients triaged based on high suPAR results, that were subsequently treated with anakinra, in addition to current SOC, experienced reduced risk of death, ICU admission and increased the likelihood of full recovery. The study was conducted by the Hellenic Institute for the Study of Sepsis. KEY HIGHLIGHTS FROM THE STUDY Early triage with suPARnostic® for medical intervention using anakinra showed considerable efficacy and reduced risk of disease progression and death by 64 percent, according to day 28
Västra Hamnen Corporate Finance Initiates Coverage of ViroGates29.1.2020 09:08:51 CET | Pressemeddelelse
ViroGates A/S (Nasdaq First North Growth Market Denmark: VIRO), who delivers blood test products, primarily for emergency departments in hospitals, today announces that Västra Hamnen Corporate Finance AB will initiate research coverage of ViroGates.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum